GDNF family receptor alpha 1-Rearranged during transfection signaling complex (GFRA1-RET)

The GDNF family receptor alpha 1-Rearranged during transfection (GFRA1-RET) signaling complex is a multicomponent receptor system primarily activated by Glial cell line-derived neurotrophic factor (GDNF) (UniProt P56159, P07949). This complex consists of GFRA1, a glycosylphosphatidylinositol (GPI)-anchored co-receptor, and RET, a transmembrane receptor tyrosine kinase (PubMed: 9060641). Upon GDNF binding to GFRA1, the complex promotes RET homodimerization and subsequent autophosphorylation of its intracellular tyrosine residues, triggering downstream signaling cascades such as the MAPK/ERK, PI3K/Akt, and PLCγ pathways (NCBI Gene ID: 5979). These pathways are critical for the development and maintenance of the enteric nervous system, renal morphogenesis, and the survival of dopaminergic neurons (PubMed: 29343474). In oncology, aberrant activation of the RET component through genetic fusions or point mutations is a well-established driver in various cancers, including medullary thyroid carcinoma and non-small cell lung cancer (PubMed: 32853545). Conversely, therapeutic strategies in neurodegeneration aim to enhance this signaling axis to promote neuronal survival. Current pharmacological interventions primarily focus on selective and multi-kinase inhibitors that target the RET kinase domain to treat RET-driven malignancies. Additionally, GFRA1 is being explored as a target for antibody-drug conjugates in solid tumors to deliver cytotoxic payloads specifically to cells overexpressing the complex (PubMed: 30139815).

Other names

GDNF family receptor alpha 1-RET complexGFRalpha1-RETRET-GFRA1 complexGDNF receptor complexGDNF-GFRA1-RET signaling axis

Small molecule inhibition of the RET tyrosine kinase domain to block downstream signaling pathways such as MAPK/ERK and PI3K/Akt.